Colorado is currently home to 1774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Creative Arts Program to Reduce Burnout in Healthcare Professionals
NCT04276922
Recruiting
This study plans to learn if creative arts programs that include visual, musical, written, or physical expression can reduce symptoms of burnout syndrome, Post Traumatic Stress Disorder (PTSD), depression, and anxiety in critical care healthcare professionals. This study also explores if creative arts can enhance the connection to the purpose of work, the development of adequate coping skills, while providing time to connect with peers.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2024
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Burn-Out Syndrome, Post-Traumatic Stress Disorder, Depression, Anxiety
Register for Updates
A Registry for People With T-cell Lymphoma
NCT05978141
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: University of Colorado (Data Collection Only), Aurora, Colorado
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: Rocky Mountain Multiple Sclerosis Center, University of Colorado School of Medicine, Aurora, Colorado
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
NCT02602262
Recruiting
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected (HIV-) donors will also be followed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: HIV Infection
Register for Updates
Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes
NCT06575842
Recruiting
This study is assessing the accuracy of continuous glucose monitors during surgical procedures requiring anesthesia.
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
12/06/2024
Locations: Barbara Davis Center, Aurora, Colorado
Conditions: Type 1 Diabetes
Register for Updates
Comparison of Methods in Post Operative Hip Arthroscopy Rehabilitation
NCT05165927
Recruiting
The investigators plan to investigate the efficacy of blood flow restriction (BFR) therapy in post operative rehabilitation following hip arthroscopy. BFR has shown to be great at helping the recovery process. SAGA is a well-known smart training technology company, and the investigators aim to partner with SAGA to use the BFR cuffs as the intervention method. The BFR cuff will be added to the current SOC for hip scope PT for the intervention group.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/06/2024
Locations: UCHealth Steadman Hawkins Clinic Denver, Englewood, Colorado
Conditions: Hip Injuries
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Rocky Mountain Cancer Center, Denver, Colorado
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Brain Oxygen Optimization in Severe TBI, Phase 3
NCT03754114
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Brain Injuries, Traumatic
Register for Updates
ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis
NCT03404258
Recruiting
This is a novel preliminary study of biomarkers of pathologic pre-operative pulmonary vascular development, elevated pre-operative Pulmonary Vascular Resistance Index (PVRi), and complications associated with decreased post-operative pulmonary blood flow in single ventricle patients undergoing superior cavo-pulmonary anastomosis (SCPA). The study will utilize a combined targeted and untargeted approach to both optimize translation of a promising existing biomarker and efficiently identify novel... Read More
Gender:
ALL
Ages:
Between 1 month and 2 years
Trial Updated:
12/06/2024
Locations: Children's Hospital Colorado, Denver, Colorado
Conditions: Single-ventricle, Pulmonary Vascular Resistance Abnormality, Superior Cavo-Pulmonary Anastomosis, Endothelin, Metabolomics
Register for Updates
The Immune System's Response to Young Women's Breast Cancer
NCT01503190
Recruiting
This study plans to learn more about the immune system's response to breast cancer in young women.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Breast Cancer, Breast Cancer and Pregnancy
Register for Updates
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
NCT06598449
Recruiting
Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the setting of fever or temperature changes such as getting in or out of bath water. Many anti-seizure medications are sodium channel blockers and exacerbate seizures in this patient population. This creates some limitations in... Read More
Gender:
ALL
Ages:
Between 12 months and 24 months
Trial Updated:
12/05/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Dravet Syndrome (DS), Children Under 2 Years
Register for Updates